The U.S. National Cancer Institute (NCI) awarded a $219,351 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The Institute For Cancer Research, a non-profit organization, to evaluate the toxicity, pharmacokinetics, and therapeutic efficacy of the drug T3 (the active form of thyroid hormone) for the treatment of medulloblastoma, the most common malignant brain tumor in children. The two-year project, running from February 2025 to January 2027, aims to provide the preclinical data necessary for designing future clinical trials to assess T3 as a potential novel therapeutic modality for medulloblastoma. This research builds on the grantee's prior discoveries that T3 can inhibit medulloblastoma tumor growth in mice without causing significant side effects, suggesting it may be a promising approach to treat this deadly pediatric cancer while minimizing long-term treatment complications.
Generated 3/4/25, 4:42 AM